NCT03916094View on ClinicalTrials.gov

Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2019

Primary Completion Date

January 4, 2021

Study Completion Date

December 27, 2021

Conditions

Solid Tumor

Interventions

DRUG

HLX22

Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody

Trial Locations (1)

Unknown

First Hospital of Jilin University, Changchun

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY

NCT03916094 - Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2 | Biotech Hunter | Biotech Hunter